LivaNova PLC (LIVN) - Total Assets
Based on the latest financial reports, LivaNova PLC (LIVN) holds total assets worth $2.52 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does LivaNova PLC reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
LivaNova PLC - Total Assets Trend (1992–2025)
This chart illustrates how LivaNova PLC's total assets have evolved over time, based on quarterly financial data. Explore LivaNova PLC (LIVN) investment intensity to see how much of total assets are deployed in long-term investments.
LivaNova PLC - Asset Composition Analysis
Current Asset Composition (December 2025)
LivaNova PLC's total assets of $2.52 Billion consist of 42.3% current assets and 57.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.4% |
| Accounts Receivable | $216.00 Million | 8.3% |
| Inventory | $164.70 Million | 6.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $230.00 Million | 8.8% |
| Goodwill | $792.80 Million | 30.4% |
Asset Composition Trend (1992–2025)
This chart illustrates how LivaNova PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of LivaNova PLC.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LivaNova PLC's current assets represent 42.3% of total assets in 2025, a decrease from 84.9% in 1992.
- Cash Position: Cash and equivalents constituted 24.4% of total assets in 2025, down from 33.3% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 38.0% of total assets, an increase from 0.0% in 1992.
- Asset Diversification: The largest asset category is goodwill at 30.4% of total assets.
LivaNova PLC Competitors by Total Assets
Key competitors of LivaNova PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Medtronic PLC
XETRA:2M6
|
Germany | €91.57 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
EBR Systems Inc
AU:EBR
|
Australia | AU$97.29 Million |
|
Aroa Biosurgery Ltd
AU:ARX
|
Australia | AU$95.27 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Bluelinea SA
PA:ALBLU
|
France | €9.50 Million |
|
elexxion AG
XETRA:E8X
|
Germany | €4.57K |
LivaNova PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.33 | 1.58 | 1.15 |
| Quick Ratio | 1.11 | 1.37 | 0.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $251.70 Million | $429.58 Million | $106.85 Million |
LivaNova PLC - Advanced Valuation Insights
This section examines the relationship between LivaNova PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.26 |
| Latest Market Cap to Assets Ratio | 1.48 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | $2.61 Billion |
| Market Capitalization | $3.85 Billion USD |
Valuation Analysis
Above Book Valuation: The market values LivaNova PLC's assets above their book value (1.48x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: LivaNova PLC's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for LivaNova PLC (1992–2025)
The table below shows the annual total assets of LivaNova PLC from 1992 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.61 Billion | +3.98% |
| 2024-12-31 | $2.51 Billion | +3.16% |
| 2023-12-31 | $2.43 Billion | +5.87% |
| 2022-12-31 | $2.29 Billion | +4.26% |
| 2021-12-31 | $2.20 Billion | -8.29% |
| 2020-12-31 | $2.40 Billion | -0.49% |
| 2019-12-31 | $2.41 Billion | -5.41% |
| 2018-12-31 | $2.55 Billion | +1.83% |
| 2017-12-31 | $2.50 Billion | +6.89% |
| 2016-12-31 | $2.34 Billion | -8.45% |
| 2015-12-31 | $2.56 Billion | +769.75% |
| 2014-12-31 | $294.19 Million | 0.00% |
| 2013-12-31 | $294.19 Million | +11.42% |
| 2012-12-31 | $264.04 Million | +24.60% |
| 2011-12-31 | $211.91 Million | +0.21% |
| 2010-12-31 | $211.47 Million | +1.93% |
| 2009-12-31 | $207.47 Million | +41.89% |
| 2008-12-31 | $146.21 Million | +39.00% |
| 2007-12-31 | $105.19 Million | -22.79% |
| 2006-12-31 | $136.23 Million | -10.55% |
| 2005-12-31 | $152.30 Million | +54.06% |
| 2004-12-31 | $98.86 Million | +4.83% |
| 2003-12-31 | $94.30 Million | -0.84% |
| 2002-12-31 | $95.10 Million | +36.06% |
| 2001-12-31 | $69.90 Million | +2.80% |
| 2000-12-31 | $67.99 Million | +69.98% |
| 1999-12-31 | $40.00 Million | +0.50% |
| 1998-12-31 | $39.80 Million | -5.46% |
| 1997-12-31 | $42.10 Million | -19.96% |
| 1996-12-31 | $52.60 Million | +1248.72% |
| 1995-12-31 | $3.90 Million | -60.20% |
| 1994-12-31 | $9.80 Million | -50.51% |
| 1993-12-31 | $19.80 Million | -21.43% |
| 1992-12-31 | $25.20 Million | -- |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. … Read more